Objective:

To evaluate the safety and neuroprotective potential of the VCP inhibitor ML240 using organotypic retinal explants from pigs, macaques, and humans, highlighting its relevance for retinal degenerative diseases.

Approach:

Key Findings:

• ML240 demonstrated a comprehensive preclinical safety profile across species, indicating its potential for broader application.
• The treatment preserved photoreceptor structure and function in retinal explants, suggesting a protective mechanism.
• Microglial reactivity was effectively managed with ML240 treatment, which may have implications for inflammatory responses in retinal diseases.

Interpretation:

The findings support the potential of ML240 as a mutation-independent therapeutic candidate for retinal degenerative diseases, showing safety and efficacy in a relevant ex vivo model, which could translate into clinical settings.

Limitations:

• The study is limited to ex vivo models, which may not fully replicate in vivo conditions, potentially affecting the translatability of results.
• The long-term effects of ML240 were not assessed in this study, which is crucial for understanding its therapeutic viability.

Conclusion:

ML240 shows promise as a therapeutic agent for retinal degenerative diseases, warranting further investigation in clinical settings, particularly focusing on long-term safety and efficacy.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.